Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.

The global epidemic of Type-2-Diabetes (T2D) highlights the need for novel therapeutic targets and agents. Roux-en-Y-Gastric-Bypass (RYGB) is the most effective treatment. Studies investigating the mechanisms of RYGB suggest a role for post-operative changes in portal glucose levels. We investigate...

Full description

Bibliographic Details
Main Authors: Atanu Pal, David B Rhoads, Ali Tavakkoli
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5091783?pdf=render
_version_ 1818908984819580928
author Atanu Pal
David B Rhoads
Ali Tavakkoli
author_facet Atanu Pal
David B Rhoads
Ali Tavakkoli
author_sort Atanu Pal
collection DOAJ
description The global epidemic of Type-2-Diabetes (T2D) highlights the need for novel therapeutic targets and agents. Roux-en-Y-Gastric-Bypass (RYGB) is the most effective treatment. Studies investigating the mechanisms of RYGB suggest a role for post-operative changes in portal glucose levels. We investigate the impact of stimulating portal glucose sensors on systemic glucose levels in health and T2D, and evaluated the role of sodium-glucose-cotransporter-3 (SGLT3) as the possible sensor.Systemic glucose and hormone responses to portal stimulation were measured. In Sprague-Dawley (SD) rats, post-prandial state was simulated by infusing glucose into the portal vein. The SGLT3 agonist, alpha-methyl-glucopyranoside (αMG), was then added to further stimulate the portal sensor. To elucidate the neural pathway, vagotomy or portal denervation was followed by αMG+glucose co-infusion. The therapeutic potential of portal glucose sensor stimulation was investigated by αMG-only infusion (vs. saline) in SD and Zucker-Diabetic-Fatty (ZDF) rats. Hepatic mRNA expression was also measured.αMG+glucose co-infusion reduced peak systemic glucose (vs. glucose alone), and lowered hepatic G6Pase expression. Portal denervation, but not vagotomy, abolished this effect. αMG-only infusion lowered systemic glucose levels. This glucose-lowering effect was more pronounced in ZDF rats, where portal αMG infusion increased insulin, C-peptide and GIP levels compared to saline infusions.The portal vein is capable of sensing its glucose levels, and responds by altering hepatic glucose handling. The enhanced effect in T2D, mediated through increased GIP and insulin, highlights a therapeutic target that could be amenable to pharmacological modulation or minimally-invasive surgery.
first_indexed 2024-12-19T22:19:42Z
format Article
id doaj.art-63d38cff839244ddb887da1f7997d506
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-19T22:19:42Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-63d38cff839244ddb887da1f7997d5062022-12-21T20:03:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011111e016559210.1371/journal.pone.0165592Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.Atanu PalDavid B RhoadsAli TavakkoliThe global epidemic of Type-2-Diabetes (T2D) highlights the need for novel therapeutic targets and agents. Roux-en-Y-Gastric-Bypass (RYGB) is the most effective treatment. Studies investigating the mechanisms of RYGB suggest a role for post-operative changes in portal glucose levels. We investigate the impact of stimulating portal glucose sensors on systemic glucose levels in health and T2D, and evaluated the role of sodium-glucose-cotransporter-3 (SGLT3) as the possible sensor.Systemic glucose and hormone responses to portal stimulation were measured. In Sprague-Dawley (SD) rats, post-prandial state was simulated by infusing glucose into the portal vein. The SGLT3 agonist, alpha-methyl-glucopyranoside (αMG), was then added to further stimulate the portal sensor. To elucidate the neural pathway, vagotomy or portal denervation was followed by αMG+glucose co-infusion. The therapeutic potential of portal glucose sensor stimulation was investigated by αMG-only infusion (vs. saline) in SD and Zucker-Diabetic-Fatty (ZDF) rats. Hepatic mRNA expression was also measured.αMG+glucose co-infusion reduced peak systemic glucose (vs. glucose alone), and lowered hepatic G6Pase expression. Portal denervation, but not vagotomy, abolished this effect. αMG-only infusion lowered systemic glucose levels. This glucose-lowering effect was more pronounced in ZDF rats, where portal αMG infusion increased insulin, C-peptide and GIP levels compared to saline infusions.The portal vein is capable of sensing its glucose levels, and responds by altering hepatic glucose handling. The enhanced effect in T2D, mediated through increased GIP and insulin, highlights a therapeutic target that could be amenable to pharmacological modulation or minimally-invasive surgery.http://europepmc.org/articles/PMC5091783?pdf=render
spellingShingle Atanu Pal
David B Rhoads
Ali Tavakkoli
Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
PLoS ONE
title Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
title_full Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
title_fullStr Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
title_full_unstemmed Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
title_short Effect of Portal Glucose Sensing on Systemic Glucose Levels in SD and ZDF Rats.
title_sort effect of portal glucose sensing on systemic glucose levels in sd and zdf rats
url http://europepmc.org/articles/PMC5091783?pdf=render
work_keys_str_mv AT atanupal effectofportalglucosesensingonsystemicglucoselevelsinsdandzdfrats
AT davidbrhoads effectofportalglucosesensingonsystemicglucoselevelsinsdandzdfrats
AT alitavakkoli effectofportalglucosesensingonsystemicglucoselevelsinsdandzdfrats